文献速递母胎医学产科生殖医学

MRAS相关Noonan综合征以肥厚型心肌病为关键特征:新病例与文献综述

Hypertrophic Cardiomyopathy as a Key Feature of MRAS-Related Noonan Syndrome: New Case and Comprehensive Literature Review.
PubMed 文献 · Prenat Diagn · 2026-03-22

Noonan综合征是RASopathy组罕见多系统疾病,由RAS/MAPK通路基因致病变异引起,PTPN11约占50%,MRAS亦相关。本文报道第八例致病性MRAS变异病例,为首例产前早发严重表现,胎儿有颈项透明层增厚、静脉导管缺如、肺淋巴管扩张及复杂肝血管异常,33周剖宫产,新生儿死于难治性休克和多器官衰竭,组织病理示肥厚型心肌病、闭塞性门静脉病和淋巴管扩张。文献提示致病性MRAS变异者肥厚型心肌病风险高(100%病例)。

要点

  • 致病性MRAS变异与Noonan综合征及严重肥厚型心肌病高度相关。
  • 产前可表现为颈项透明层增厚、静脉导管缺如、淋巴管扩张和肝血管异常。
  • MEK抑制剂等靶向治疗可能为潜在方向,但需进一步研究验证。

核心结论

  • 致病性MRAS变异 confers 高风险的严重肥厚型心肌病(100%病例)。
  • MEK抑制剂等靶向治疗提供潜在治疗可能。

研究设计与样本

  • 病例报告加文献综述,报道第八例致病性MRAS变异Noonan综合征病例。
  • 该病例为首例记录有产前早发严重表现的病例。

主要发现

  • 胎儿表现为颈项透明层增厚、静脉导管缺如、肺淋巴管扩张和复杂肝血管异常。
  • 33周因胎儿胸腔积液加重和母体羊水过多不耐受行剖宫产。
  • 新生儿死于难治性休克和多器官衰竭。
  • 组织病理显示肥厚型心肌病、闭塞性门静脉病和淋巴管扩张。

关键数值与推荐

  • 文献汇总显示致病性MRAS变异者肥厚型心肌病发生率为100%。
  • PTPN11基因约占Noonan综合征病例的50%。

临床怎么用

  • 对产前发现颈项透明层增厚、静脉导管缺如、淋巴管扩张和肝血管异常的胎儿,应考虑MRAS相关Noonan综合征。
  • 致病性MRAS变异胎儿需警惕严重肥厚型心肌病和不良围产结局。

局限性

  • 基于单病例报告和文献综述,证据级别有限。
  • 靶向治疗MEK抑制剂的潜在疗效尚未在临床研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Noonan syndrome (NS) is a rare multisystemic condition among the RASopathy group, characterized by a broad phenotypic spectrum and genetic variability. It results from pathogenic variants in genes regulating the RAS/MAPK pathway, affecting cell proliferation and differentiation. While the PTPN11 gene accounts for approximately 50% of cases, other genes, including MRAS, have been implicated. NS presents with features such as facial dysmorphism, short stature, and cardiac anomalies. Hypertrophic cardiomyopathy (HCM) is a major contributor to mortality, with specific variants conferring higher risk. This article includes a review of the literature on NS with pathogenic MRAS variants and describes an eighth case, the first documented with early and severe antenatal manifestations. The fetus exhibited increased nuchal translucency, agenesis of the ductus venosus, pulmonary lymphangiectasia, and complex hepatic vascular anomalies. A cesarean section was performed at 33 weeks' gestation due to worsening fetal pleural effusions and maternal intolerance to polyhydramnios. Despite intensive postnatal care, the newborn died from refractory shock and multi-organ failure. Histopathology revealed HCM, obliterative portal venopathy and lymphangiectasia, consistent with NS pathology. These findings suggest that pathogenic MRAS variants confer a high risk of severe HCM (100% of cases). Moreover, emerging targeted therapies, such as MEK inhibitors, offer potential for treatment.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Martineau R, Wells C, Fuchs F, et al. Hypertrophic Cardiomyopathy as a Key Feature of MRAS-Related Noonan Syndrome: New Case and Comprehensive Literature Review. Prenat Diagn. 2026. PMID: 41866303. doi:10.1002/pd.70134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。